Prothena Q3 2026: Net Loss Narrows to $16.5M, Cash $272.2M, Burn Guidance Held
PRTA is trading near its 52-week low of $7.73 (2.1% above the low).
Summary
Prothena reported a Q3 2026 net loss of $16.5 million, down from $36.5 million a year ago, with $272.2 million of cash and no debt. Full-year burn guidance of $18-23 million was reaffirmed, leaving the pipeline funded through the 2029 Phase 3 readouts.
Key Events · Earnings and Guidance · PRTA
-
Q3 Loss Narrows Sharply
Net loss was $16.5 million ($0.32 per share) versus $36.5 million ($0.68) a year ago; nine-month net loss fell to $2.4 million from $222.5 million.
-
Cash Position and Burn Guidance
Cash, equivalents and restricted cash totaled $272.2 million at September 30, 2026, with no debt. Full-year 2026 net cash used in operations and investing is guided to $18-23 million, ending the year near $259 million.
-
Revenue Boosted by Novo Milestone
Total revenue was $52.7 million for the first nine months of 2026, primarily a $50.0 million milestone from Novo tied to the coramitug Phase 3 trial; Q3 revenue alone was just $0.6 million.
-
Buyback Nearly a Third Deployed
2,745,380 shares were repurchased in the first nine months of 2026 for $26.6 million under the up-to-$100 million program, which expires December 31, 2026. About 51.3 million shares were outstanding as of October 29, 2026.
Analysis · PRTA · Life Sciences
The headline is the balance sheet, not the P&L. Prothena's quarterly loss shrank to $16.5 million from $36.5 million a year ago, helped by R&D spending collapsing to $8.4 million from $28.9 million after the company wound down its internal programs. Cash of $272.2 million and no debt against full-year burn guidance of just $18-23 million funds operations well past the 2029 Phase 3 readouts for prasinezumab and coramitug. That runway matters more than usual right now: Bristol Myers Squibb is terminating the PRX019 license effective January 28, 2027, removing a partnered revenue stream, and the low burn rate is what absorbs that loss. With the stock near its 52-week low of $7.73, the market is already pricing skepticism; today's numbers show the cash runway is not the problem.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, PRTA was trading at $7.89 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $405M. The 52-week trading range was $7.73 to $11.80. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.